investor intrigu take wait
bottom line numer convers investor
last week sinc publish detail look combin
bristol/celgen host investor lunch discuss bull bear thesi
stock chat variou investor provid
detail feedback investor convers gener
theme like valu name
also rush get stock ahead upcom data readout
close celgen acquisit
focu expect note last week focus
asset celgen bring combin compani
oppos bristol alreadi howev surpris
much focus investor seem right upcom lung
cancer data part opdivo yervoy part
opdivo chemo could investor look get bristol
wait data point clear first consist heard
expert spoke expect posit data
seem quit low although seri underwhelm dataset opdivo
opdivo yervoy lung cancer seem keep investor
sidelin data pass convers suggest downsid
possibl disappoint data potenti upsid
data suggest bristol get meaning share line non-smal
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
bristol-my squibb compani bm engag discoveri
develop licens manufactur market distribut
sale pharmaceut product global basi
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
opdivo/i-o eliqui yervoy compar current base case
assumpt blue sky valuat base dcf driven
wacc termin valu
grey sky valuat base lower sale opdivo/i-
eliqui yervoy compar current base case assumpt
grey sky valuat base dcf driven wacc
 close
limit enthusiasm celgen main focu investor
celgen pipelin ozanimod given assum accept
regulatori file fda past mark debat
product obtain level sale celgen manag previous
suggest recent call multipl sclerosi expert suggest limit
opportun drug market numer oral avail
mani current like futur competitor target inflammatori
bowel diseas market well celgen make progress hit import
mileston pipelin highlight today fda accept
luspatercept file beta-thalassemia indic receiv prioriti review
design provid us investor increment insight
key celgen pipelin asset notabl liso-cel fedratinib today
transcend data cll show promis data liso-cel heavily-pretr
patient initi data iberdomid interest investor spoke
wonder commerci opportun crowd multipl myeloma market also
saw addit data relat celgen
deal seem provid investor renew optim bristol/nektar
collabor given deeper respons patient either metastat
melanoma metastat urotheli carcinoma excit around
decreas significantli sinc still clearli hold potenti
viabl agent add top opdivo opdivo yervoy rang tumor type
expect addit phase studi start announc collabor
come month current oct deadlin indic
phase trial start could revert back nektar
pressur manag deliv may thing investor
fulli expect bristol/celgen deal close like late quarter
ftc request addit inform focus compani psoriasi asset
expect meaning divestitur need certainli expect
bristol hold otezla tyk inhibitor investor also
limit doubt bristol abl obtain synergi
deal guid although question remain whether
select right synergi extract without disrupt either develop
commerci side busi one way investor gener believ
manag team make sure beat rais estim next sever
quarter work regain trust investor commun whether
also lead multipl expans stock price appreci
debat mani investor say despit stock look cheap dcf
pro forma price-to-earnings basi remain good reason stock trade level
discount group
compani mention price
